Agalimmune Receives New Funding

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    2875 Michelle Drive Irvine, CA 92606 USA
  • Company Description
    At Agalimmune we see harnessing and directing the protective power of the immune system as being a cornerstone of cancer therapy, now and into the future. Cancer is responsible for 13% of deaths worldwide and it is estimated that one in three of us will have cancer at some point in our lives.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
  • Proceeds Purposes
    The investment will be used to fund Agalimmune’s research into combination therapy with immune checkpoint inhibitors such as the CTLA-4, PD-1, and PD-L1 classes of compounds, as part of its supportive preclinical work packages.
  • M&A Terms
  • Venture Investor
  • Venture Investor

Trending on Xconomy